CHAPEL HILL, N.C. … Pharmaceutical development firm Pozen (Nasdaq: POZN) says a second study comparing MT 100, its experimental migraine drug, to GlaxoSmithKline’s Imitrex, the leading migraine product in the United States, showed both drugs are similarly effective.

More than 1,000 migraine patients completed this double-blind, placebo-controlled trial at 41 centers nationwide. The trial results indicate that a single tablet dose of MT 100 provided comparable efficacy to Imitrex 50 mg. and was superior to placebo for both two-hour pain relief and sustained pain relief, confirming the results of a previously completed Phase III trial.

The U.S. Food and Drug Administration usually requires at least two studies with similar results to support promotional claims. MT 100 is being developed as an oral, first-line treatment for migraine.

Pozen has completed all planned Phase III pivotal trials for MT 100, which has consistently demonstrated its effectiveness in treating migraine pain with less risk of cardiovascular side effects compared to leading products on the market today.